 NEW YORK and WALTHAM, Mass., Jan. 19, 2021 GLOBE NEWSWIRE -- Royalty Pharma plc Nasdaq: RPRX and Minerva Neurosciences, Inc. Nasdaq: NERV today announced that Royalty Pharma will acquire Minervas royalty interest in seltorexant for an upfront payment of 60 million and up to 95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones. 